Ring therapeutics

Biotechnology company based in Cambridge, Massachusetts, focusing on the development of Anellovector™ therapeutics. The company is pioneering a redosable and targetable gene therapy platform by leveraging the human commensal virome, aiming to expand gene therapy applications beyond gene replacement. Ring Therapeutics primarily targets patients with previously inaccessible diseases, offering new treatment modalities and mechanisms.